Arunjyoti Bio

how big is Arunjyoti Bio?

As of Jun 06, Arunjyoti Bio Ventures Ltd has a market capitalization of 137.00 Cr, classifying it as a Micro Cap company, with recent net sales of 0.38 Cr and net profit of 0.10 Cr. Shareholder's funds are reported at 1.81 Cr, and total assets amount to 2.22 Cr.

Market Cap: As of Jun 06, Arunjyoti Bio Ventures Ltd has a market capitalization of 137.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the sum of Net Sales is 0.38 Cr and the sum of Net Profit is 0.10 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'10. The Shareholder's Funds are reported at 1.81 Cr, and the Total Assets amount to 2.22 Cr.

Has Arunjyoti Bio declared dividend?

No Dividend History Available

Who are the peers of the Arunjyoti Bio?

Arunjyoti Bio's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Thacker & Co., Tilak Ventures, Delphi World, and Landmarc Leisur. In terms of performance, Bajaj Finance leads with a 1-year return of 30.40%, while Arunjyoti Bio has a return of 4.31%.

Peers: The peers of Arunjyoti Bio are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Thacker & Co., Tilak Ventures, Delphi World, Landmarc Leisur.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial and Thacker & Co., and Below Average management risk is noted at Tilak Ventures, Delphi World, Landmarc Leisur., and Arunjyoti Bio. Growth is Excellent for Jio Financial and Arunjyoti Bio, Good for Bajaj Finance and Cholaman.Inv.&Fn, and Average for Tilak Ventures, while Below Average growth is seen at Thacker & Co. and Delphi World. Capital Structure is Excellent for Bajaj Finance, Jio Financial, Shriram Finance, and Muthoot Finance, Good for Thacker & Co., and Average for Arunjyoti Bio, with Below Average capital structure at Tilak Ventures, Delphi World, and Landmarc Leisur.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bajaj Finance at 30.40%, while the lowest is Jio Financial at -20.23%. Arunjyoti Bio's 1-year return is 4.31%, which is significantly higher than Jio Financial's but lower than Bajaj Finance's. Additionally, the six-month returns for Jio Financial, Thacker & Co., Tilak Ventures, Delphi World, and Landmarc Leisur. are negative.

Is Arunjyoti Bio overvalued or undervalued?

As of March 21, 2024, Arunjyoti Bio is considered very expensive with a PE ratio of -75.77 and unfavorable financial metrics, significantly underperforming against peers and the Sensex.

As of 21 March 2024, the valuation grade for Arunjyoti Bio has moved from risky to very expensive. This indicates a significant shift in perception, suggesting that the company is now considered overvalued. The current PE ratio stands at -75.77, while the EV to EBITDA ratio is 32.86, and the Price to Book Value is 4.28. These ratios highlight a concerning financial position, particularly with a negative ROE of -5.65% and a low ROCE of 3.38%.<BR><BR>In comparison to its peers, Arunjyoti Bio's valuation metrics are starkly unfavorable. For instance, Life Insurance has a PE ratio of 12.54 and an EV to EBITDA of 9.89, both indicating a more reasonable valuation. Similarly, Bajaj Finance, categorized as very expensive, has a PE ratio of 35.01, which still pales in comparison to Arunjyoti Bio's negative valuation metrics. The company's stock has underperformed significantly against the Sensex, particularly year-to-date with a decline of 63.28% compared to the Sensex's gain of 5.62%. Overall, Arunjyoti Bio appears to be overvalued given its financial ratios and peer comparisons.

What is the technical trend for Arunjyoti Bio?

As of April 30, 2025, Arunjyoti Bio's technical trend has shifted to bearish, supported by bearish signals from the MACD, Bollinger Bands, and moving averages, indicating a weak bearish sentiment in the market.

As of 30 April 2025, the technical trend for Arunjyoti Bio has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly MACD and Bollinger Bands, both signaling bearish conditions. The daily moving averages also confirm a bearish trend. The KST on a weekly basis is bearish, while the monthly KST remains mildly bearish. Dow Theory reflects a mildly bearish stance on the weekly and monthly time frames. Overall, the indicators suggest a weak bearish sentiment in the market for Arunjyoti Bio.

Who are in the management team of Arunjyoti Bio?

As of March 2022, the management team of Arunjyoti Bio includes Polsani Venkata Rama Rao (Non-Executive & Independent Director), Raja Kumar Babulal (Whole-time Director), Pabbathi Praveen Kumar (Whole Time Director & CFO), M Aditya Vardhan Reddy, D Vanaja Kumari, and K Chandra Sekhar (all Non-Executive & Independent Directors), along with Swati Jain (Company Secretary & Compliance Officer). The team consists of both executive and non-executive members.

As of March 2022, the management team of Arunjyoti Bio includes the following members:<BR><BR>1. Polsani Venkata Rama Rao - Non-Executive & Independent Director<BR>2. Raja Kumar Babulal - Whole-time Director<BR>3. Pabbathi Praveen Kumar - Whole Time Director & CFO<BR>4. M Aditya Vardhan Reddy - Non-Executive & Independent Director<BR>5. D Vanaja Kumari - Non-Executive & Independent Director<BR>6. K Chandra Sekhar - Non-Executive & Independent Director<BR>7. Swati Jain - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and non-executive directors, along with a compliance officer.

What does Arunjyoti Bio do?

Arunjyoti Bio Ventures Ltd is a micro-cap NBFC specializing in co-packing services for beverages, with a market cap of INR 108 Cr. As of March 2025, it reported net sales of 53 Cr and a net loss of 20 Cr.

Overview:<BR>Arunjyoti Bio Ventures Ltd is a micro-cap company in the Non-Banking Financial Company (NBFC) sector, specializing in high-quality co-packing services for beverages.<BR><BR>History:<BR>Established in 1986, Arunjyoti Bio Ventures Ltd was formerly known as Century 21st Portfolio Limited. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 53 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -20 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 108 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 23<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.81<BR>- Return on Equity: -5.65%<BR>- Price to Book: 3.33<BR><BR>Contact Details:<BR>Address: Plot No 45 P&T Colony, Karkhana Secunderabad Telangana : 500009<BR>Tel: 91-44-66684223<BR>Email: cenport@gmail.com<BR>Website: http://www.century21st.in

Who are the top shareholders of the Arunjyoti Bio?

The top shareholders of Arunjyoti Bio are Dathvik Pabbhathi, the promoter with 23.07%, and public shareholder Chennupati Sarath Kumar with 13.14%. Individual investors hold a combined 49.59%, with no institutional or pledged promoter holdings.

The top shareholders of Arunjyoti Bio include Dathvik Pabbhathi, who is the promoter with the highest holding at 23.07%. The highest public shareholder is Chennupati Sarath Kumar, holding 13.14%. Additionally, individual investors collectively hold 49.59% of the shares. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

When is the next results date for Arunjyoti Bio?

The next results date for Arunjyoti Bio is November 3, 2025.

The next results date for Arunjyoti Bio is scheduled for November 3, 2025.

How has been the historical performance of Arunjyoti Bio?

Arunjyoti Bio's historical performance shows a decline in net sales from 0.43 crore in March 2010 to 0.08 crore in September 2010, but profitability metrics improved, with profit after tax rising from 0.03 crore to 0.04 crore and a significant increase in operating profit margin from 2.3% to 51.19%.

Answer:<BR>The historical performance of Arunjyoti Bio shows a modest growth in net sales and profitability over the reported periods.<BR><BR>Breakdown:<BR>In the financial results for the periods ending March 2010 and September 2010, Arunjyoti Bio reported net sales of 0.43 crore and 0.08 crore respectively, indicating a decline in total operating income from 0.43 crore in March 2010 to 0.08 crore in September 2010. The total expenditure, excluding depreciation, also decreased from 0.42 crore to 0.04 crore during the same period. Operating profit (PBDIT) showed a slight increase from 0.09 crore in March 2010 to 0.07 crore in September 2010, while profit before tax rose from 0.04 crore to 0.06 crore. Profit after tax also increased from 0.03 crore to 0.04 crore, reflecting a PAT margin of 50.0% in September 2010 compared to 6.67% in March 2010. The earnings per share (EPS) improved from 0.15 to 0.20, and the operating profit margin (excluding other income) significantly increased from 2.3% to 51.19%. Overall, while there was a decline in sales, the company managed to improve its profitability metrics in the latter period.

Are Arunjyoti Bio Ventures Ltd latest results good or bad?

Arunjyoti Bio Ventures Ltd's latest results show a mixed performance, with a net profit of ₹0.87 crores for FY26 but recent losses leading to a negative ROE of -6.76%. Concerns about overvaluation, significant stock underperformance, and low institutional interest suggest a cautious outlook despite some positive indicators.

The latest results for Arunjyoti Bio Ventures Ltd present a mixed picture. For the nine-month period of FY26, the company reported a net profit of ₹0.87 crores, which is a positive year-on-year improvement. However, the overall financial performance has been characterized by volatility and concerns regarding its valuation.<BR><BR>Key highlights include a strong return on equity (ROE) of 29.81%, indicating effective capital utilization when the company is profitable. However, this is contrasted by a recent negative ROE of -6.76%, suggesting losses in the most recent period, which raises concerns about the sustainability of its profitability.<BR><BR>On the valuation front, the company trades at a price-to-book value of 3.94x, which is considered a premium and raises questions about whether the stock is overvalued given its modest operational scale and inconsistent profitability. The Mojo Score of 16 out of 100 indicates a "Strong Sell" rating, reflecting poor performance across various metrics.<BR><BR>Additionally, the stock has severely underperformed over the past year, declining by 49.66%, while the broader market has gained. This underperformance, combined with zero institutional interest and a significant reduction in promoter holding, adds to the concerns surrounding the company's future prospects.<BR><BR>In summary, while there are some positive aspects, such as the recent profit and strong historical ROE, the overall outlook is cautious due to valuation concerns, recent losses, and significant stock underperformance.

Should I buy, sell or hold Arunjyoti Bio Ventures Ltd?

Why is Arunjyoti Bio Ventures Ltd falling/rising?

As of 02-Jun, Arunjyoti Bio Ventures Ltd's stock price is 5.39, down 0.19%. The stock has declined significantly over the year and month, trading below key moving averages, indicating a bearish trend despite a slight outperformance in today's sector performance.

As of 02-Jun, Arunjyoti Bio Ventures Ltd's stock price is currently at 5.39, reflecting a slight decrease of 0.01 or 0.19%. The stock has shown a significant decline over various periods, with a year-to-date drop of 36.21% and a one-month decrease of 21.88%. This downward trend is further highlighted by the stock's performance compared to the benchmark Sensex, which has only fallen by 12.40% year-to-date. <BR><BR>Despite today's performance indicating that the stock has outperformed its sector by 0.68%, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a bearish trend in the stock's price movement. <BR><BR>Additionally, while there has been a rise in investor participation, with delivery volume increasing by 8.33% against the 5-day average, the overall negative performance over the longer term and the current trading below moving averages indicate that the stock is experiencing a decline rather than a rise.

Which are the latest news on Arunjyoti Bio?